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Summary Extramedullary plasmacytomas (EMP) of head and neck are rare tumours. Between 1972 and 1993, 25 cases of EMP of head
and neck were seen at our institute. The clinical and pathological features and response to treatment are presented. At initial presentation, 23
(92%) patients presented with disease confined to a single extramedullary site only and two patients had in addition clinical involvement of
cervical lymph nodes. All except these two patients received radiotherapy to the primary site only as initial treatment. Initial primary control of
local disease was obtained in 16 of 24 (67%) patients treated with radical intent. With salvage treatment of further radiotherapy and/or
chemotherapy, local disease control was achieved in 21 of 24 (88%) patients. One patient was treated with palliative intent. Conversion to
multiple myeloma was seen in two patients (8%). Pathologically, the tumours were classified into low, intermediate and high grade, which
correlated closely with outcome. This classification has been used for the first time in extramedullary plasmacytomas and is based on the
multiple myeloma grading criteria devised by Bartl et al (1987). Fifteen of eighteen (83%) low-grade tumours and only one of six (17%)
intermediate- and high-grade tumours were locally controlled after primary radiotherapy. This is statistically significant for local control (P=
0.0019) but not for overall survival (P= 0.12). The median survival and 5-year overall survival is 68 months and 58.9% respectively. We
recommend consideration of adjuvant chemotherapy in patients with higher grade disease.
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Extramedullary plasmacytoma (EMP) is a rare tumour which
accounts for less than 1-2% of all plasma cell neoplasms, and any
extra medullary organ ortissue may be involved. Eighty per cent of
these tumours originate in the head and neck region, commonly in
subepithelial tissues of the upper air passages including the
paranasal sinuses (Wiltshaw, 1976). EMPpatients characteristically
present with localized disease and the incidence of lymph node
involvement is 10-20%. Progression to multiple myeloma is signif-
icantly lower than that seen in solitary plasmacytoma ofbone. The
rarity ofthis tumour and its long natural history make determination
of prognostic factors difficult. Most reports in the literature are of
single cases, although a few series include up to 20 cases. Radiation
therapy (XRT) is generally accepted as the treatment ofchoice. The
role ofchemotherapy for localized tumour is not well defined.
This paper is a review of 25 cases of EMP ofthe head and neck
region seen at the Christie Hospital, Manchester, UK, overa 22-year
period. The principal objectives are to (1) elucidate prognostic
factors from pathological review, (2) define any dose-response rela-
tionship ofradiation therapy, (3) evaluate the role ofchemotherapy
as an adjuvant with respect to its effect as salvage treatment and (4)
determine other prognostic factors from following the natural
history ofthe disease.
MATERIALS AND METHODS
There were 25 cases of EMP of the head and neck region seen in
the 22-year period between 1972 and 1993 at the Christie Hospital.
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The patients were diagnosed as having an EMP if they met the
following criteria: (1) a biopsy-proven plasma cell tumour
involving a single extramedullary site with or without lymph node
involvement, (2) a bone marrow biopsy showing less than 5%
plasma cells and (3) normal skeletal survey. The presence of a
monoclonal band on serum protein electrophoresis or the presence
of Bence Jones protein in urine did not exclude patients from this
analysis. Bone destruction in conjunction with the extramedullary
mass did not exclude a patient from being classified as having
EMP, provided that the bony involvement was in direct continuity
with the tumour mass.
The median age of the patients was 68 years (range 27-84
years) and there was a strong male preponderance (M/F 23:2).
Nearly two-thirds presented with disease in the nasal cavity,
sinuses or nasopharynx (Table 1). Two patients (8%) had clinical
involvement of a cervical lymph node at presentation. One patient
(4%) had an IgA monoclonal band on serum protein elec-
trophoresis and three patients (12%) showed evidence of adjacent
bony destruction at the time of diagnosis. The median follow-up
for all patients was 73 months (range 2-180 months).
Histological technique
The histological sections of each case were reviewed. Paraffin
sections were cut at 4gm when tissue blocks were available; other-
wise unstained sections sent by laboratories in the referring hospi-
tals were used. All cases were stained with haematoxylin and eosin
(H and E). When the H and E appearances were suggestive of
amyloid deposition, a Congo red stain was performed. Immuno-
histochemistry was performed using a standard streptavidin-
peroxidase complex technique with diaminobenzidine chromogen
substrate. All cases were examined immunohistochemically for
kappa and lambda light chains. When additional sections were
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Table 1 Sites at presentation
Nasal cavity and sinuses 11
Nasopharynx 5
Tonsil 3
Larynx 2
Middle ear 1
Soft palate 1
Parotid 1
Posterior-pharyngeal wall 1
Total 25
Figure 2 Plasmacytoma of intermediate grade. The plasma cells exhibit
asynchronous maturation. Many cells contain large eccentric nuclei with
prominent nucleoli and abundant basophilic cytoplasm
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Figure 1 Low-grade plasmacytoma containing mature Marschalko type
plasma cells
available, immunohistochemistry for IgA, IgG and IgM was also
carried out (five cases). All antibodies were obtained from Dako,
and pretreatment was 4.5 mintrypsin digestion in all cases. Positive
and negative controls were employed for all special stains.
Histological grading
The diagnosis ofplasmacytoma required areas with closely packed
sheets consisting entirely ofplasma cells to the exclusion of other
cell types. Cases were graded according to the histological grading
criteria devised by Bartl et al (1987) for multiple myeloma (MM).
This involves a three-tiered grading system which is summarized
as follows:
Grade 1 (low grade). Figure 1 shows a marschalko type in
which the plasma cells are indistinguishable from normal cells,
although mitotic figures can be seen (also includes the small-
cell type).
Grade 2 (intermediate grade). Figure 2 shows the asynchronous
type in which there is marked discrepancy of maturation between
nucleus and cytoplasm. At least 50% of the cells have enlarged
nuclei with prominent nucleoli while the abundant basophilic
cytoplasm and perinuclear hof are maintained.
Grade 3 (high grade). Figure 3 shows a plasmablastic type with
large nuclei and very prominent centrally located nucleoli.
Cytoplasm is confined to a fairly narrow rim. Perinuclear hof are
inconspicuous or absent.
*. W.sr. _ F' t ' - v | - C P
Figure 3 High-grade plasmacytoma. Many cells exhibit plasmablastic
features with frequent mitoses
Management
Following biopsy confirmation and myeloma screening, cases
were managed with primary XRT alone. All cases treated with
radical intent were treated with megavoltage photon therapy. The
volume of treatment field included the primary site only. No
attempts were made to electively treat the cervical lymph nodes. A
patient with primary disease in tonsil and neck node was treated
with a large field encompassing primary disease and cervical
lymph node. One patient refused treatment for a period of 2 years
but later agreed to palliative treatment after becoming sympto-
matic. Over the period of22 years, a variety ofdoses were admin-
istered, the commonest being 35-45 Gy in 3 weeks with five
fractions per week.
RESULTS
Pathology
Details oftreatment, histological review and outcome are shown in
Table 2. Eighteen patients (72%) had a grade 1 plasmacytoma on
initial biopsy (17 Marschalko type; one small-cell type). In five
patients (20%), the initial tumour was grade 2 (asynchronous type)
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and in one (4%) it was grade 3 (plasmablastic). The plasmablastic
tumour was leucocyte common antigen and CD20 negative. In one
case (4%), the tumour grade varied between different areas and
had a dual low-grade (Marschalko) and intermediate-grade (asyn-
chronous) appearance. Although most cases were composed of
sheets of neoplastic plasma cells, additional histological patterns
were sometimes noted. A prominent pseudoangiomatoid appear-
ance was seen in five cases (four low grade, one intermediate
grade) (Figure 4). Two low-grade tumours had focal areas in which
the neoplastic plasma cells had acquired a spindle cell morphology
and in one of these there was even a vague storiform pattern as a
result of stromal fibrosis (Figure 5). Although mitotic figures were
numerous in the high-grade tumour, we also encountered mitotic
activity in cases with a low-grade morphology and, in one ofthese,
the mitotic count reached 20 per 10 high-power fields (Leitz
Dialux EB microscope using x 40 objective).
Two grade 1 tumours (8%) had abundant stromal amyloid and in
one of these there was an associated multinucleate giant cell reac-
tion. One tumour exhibited bone formation in the stroma. Sixteen
cases (64%) showed kappa light chain restriction, seven (28%)
showed lambda restriction, and in two cases (8%) immunostaining
for light chains was equivocal. Of the five cases (20%) for which
immunohistochemistry forimmunoglobulins was performed, clon-
ality for IgG (two cases) or IgA (one case) was demonstrated. In
the other two cases, IgG, IgA and IgM were negative.
Treatment and outcome
The primary tumour was initially controlled in 16 of 24 patients
(67%) treated with radical intent. Two ofthem were salvaged with
further XRT after local recurrence developed at 60 and 70 months.
One patient had nodal recurrence at 3 months outside the treatment
Table 2 Analysis of patients
Case Age/Sex Site Histology Radiotherapy Clinical course Outcome
1. 48/M Nasopharynx
2.
3.
4.
68/M
72/M
53/M
Tonsil
Nasopharynx
Tonsil
5. 57/M Nasal cavity
6. 42/M Nasopharynx
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
73/M
70/M
65/M
79/M
68/M
79/F
53/M
74/M
84/M
27\M
Nasopharynx
Antrum
Middle ear
Nasal cavity
Parotid
Larynx
Nasal cavity
Nasopharynx
Ethmoid
Antrum
17. 78\M Posterior pharyngeal wall
18. 68\M Tonsil with neck node
19.a 63/M Nasal cavity node
20. 57/F Antrum
21. 39/M Nasal cavity
22. 72/M Soft palate
23. 65/M
24. 74/M
25. 47/M
Larynx
Nasal cavity
Ethmoid
L, K, amyloidosis++
L, La
L, K
L, La
L, K
L, equivocal
L, K
L, equivocal
L, K
L, La
L, K (Ig raised)
L, K
L, K
L, La
L, La
L, La
L, K, amyloidosis++
L, K
L, K,
I, K
I,K
L, I, K
I, K
I, La
H, K
40 Gy in 3 weeks
50 Gy in 3 weeks
40 Gy in 3 weeks
35 Gy in 3 weeks
45 Gy in 3 weeks
45 Gy in 3 weeks
45 Gy in 3 weeks
45 Gy in 3 weeks
30 Gy in 1.5 weeks
(Bone destruction +)
35 Gy in 1.5 weeks
LR 60 months
Treated with XRT
Developed MM at 120 months
Treated with M and P
(Bone destruction +)
LR at 48 months
Treated with M and P
LR at 4 months
Treated with M and P
25 Gy in 1.5 weeks
35 Gy in 1.5 weeks
45 Gy in 3 weeks
45 Gy in 3 weeks
35Gyin3weeks
40 Gy in 3 weeks
35 Gy in 1.5 weeks
30 Gy in 3 weeks
25 Gy in 1.5 weeks
45 Gy in 4 weeksb
45 Gy in 3 weeks
37.5 Gy in 1.5 weeks
45 Gy in 3 weeks
37.5 Gy in 1.5 weeks
37.5 Gy in 3 weeks
(Bone destruction +)
Palliative XRT
LR at 12 months
Treated with surgery
LR at 48 months
Treated with M and P
NR at 2 months
Treated with XRT
Developed MM at 6 months
Treated with M and P
LR at 70 months
Treated with XRT
LR at 26 months
Treated with HD chemotherapy
and PBSC transplantion
LC, died at 144 months from MM
LC at 56 months, died from CVA
LC at 48 months, died from Ml
LC at 180 months, died from
unknown cause
LC at 24 months, died from Ml
DOD at 70 months
LC at 38 months, died from Ml
LC at 41 months, died from Ml
DOD at 24 months
LC at 72 months, died from lung
cancer
LC at 72 months
LC at 132 months
LC at 6 months, died from Ml
LC at 44 months
LC at 30 months
LC at 84 months
LC at 61 months, died from CVA
LC at 2 months, died from
unknown cause
DOD at 29 months
LC at 74 months
DOD at 59 months
LC and NC at 66 months AWD
LC at 52 months
LC at 82 months
LC at 45 months
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aRefused initial treatment. bReceived XRT at a different centre. L, low grade; I, intermediate grade; H, high grade; M, melphalan; P, prednisolone; HD, high dose
K, kappa light chain restriction; La, lambda light chain restriction; AWD, alive with disease; DOD, died of disease; CVA, cereberal vascular accident; Ml,
myocardial infarction, LC, local control; LR, local relapse; NC, nodal control; NR, nodal relapse.
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Figure 4 Plasmacytoma showing pseudoangiomatous appearance
Table 3 Local control with histological grade
Grade Initial control Control after salvage
Low 15/18 (83%) 16\18 (89%)a
Intermediate 1/5 (20%) 4\5 (80%)b
High 0/1 1\1
aOne patient developed MM and died with local control. bOne patient
developed MM and is alive with local control.
field and received XRT to the neck. All three reirradiated patients
achieved local and nodal control. Thus, 19 of 24 patients (79%)
were controlled with radiotherapy alone. One patient with local
recurrence was salvaged by high-dose chemotherapy with periph-
eral blood stem cell rescue, while one patient had salvage surgery.
Both remain in remission giving an overall rate of local control of
88% (21 of 24). One patient was treated with palliative intent.
All the unsalvagable failures (three patients) had a trial of
chemotherapy with melphalan and prednisolone. The three (13%)
radically treated relapse patients and the patient treated with
palliative intent died with uncontrolled primary disease. In total,
10 patients (40%) died of unrelated causes. The median survival
and 5-year overall survival was 68 months and 58.9% respectively.
Two of the three patients having adjacent bony destruction
recurred locally. There was no documented serious morbidity,
including those patients who underwent retreatment.
The correlation with histological grade is shown in Table 3. For
low-grade tumours, initial local control was achieved in 83% (15
of 18) patients. One ofthem was salvaged with further XRT giving
local control in 16 of 18 patients (89%). However, the patient with
recurrent low-grade tumour went on to develop disseminated bone
disease/myeloma at 120 months. The two remaining recurrent
patients were treated with melphalan and prednisolone chemo-
therapy as disease extent precluded salvage by surgery. Both of
them died with uncontrolled local disease.
Six patients were radically treated in the intermediate- and high-
grade tumour group, and only one patient achieved initial local
control with XRT. Three of the five were salvaged with further
treatment. The patient with combined low- and intermediate-grade
tumour had nodal recurrence and was treated with further XRT. He
developed disseminated bone disease - myeloma at 6 months after
Figure 5 Vague storiform pattern in a plasmacytoma
primary XRT and is alive with control of primary and nodal
disease. One ofthe intermediate-grade patients received palliative
XRT. It is interesting to note that his initial tumour from the nasal
cavity was low grade but subsequent nodal biopsy showed inter-
mediate grade. The tumour exhibiting plasmablastic features
recurred 26 months after treatment, the recurrence being a low-
grade plasmacytoma. The patient was subsequently salvaged using
high-dose chemotherapy with peripheral blood stem cell rescue.
The local control difference is highly significant (P=0.0019)
between the group oflow-grade tumours and the group ofinterme-
diate- and high-grade tumours. The overall survival is not signifi-
cant (P=0.12) between these groups.
Seven ofthe sixteen cases with kappa light chain restriction and
one ofthe seven cases with lamda light chain restriction developed
local recurrence. Both patients who progressed to multiple
myeloma had kappa light chain restriction. Two patients showed
abundant stromal amyloid on their biopsy specimen; one of them
recurred locally and further progress to multiple myeloma, while
the second patient died ofcerebral vascular accident at 61 months
after treatment with no evidence of disease. A patient with a
monoclonal band on serum protein electrophoresis on diagnosis
remains in remission 72 months after treatment.
DISCUSSION
Incidence
Extramedullary plasmacytomas (EMP) are uncommon tumours
and comprise only a small percentage ofall plasma cell malignan-
cies. Pahor (1977), quoting the Birmingham Regional Cancer
Registry, gives the ratio of incidence of EMP to MM as 1:40. At
our hospital, we see about one case of EMP of head and neck
region for an annual average of 80 myeloma registrations.
Seventy-five to eighty per cent of EMP cases occur in the submu-
cosa ofthe upper aerodigestive tract. The most common location is
in the nasal cavity, sinuses and nasopharynx. Men are predomi-
nantly affected, and these tumours are more commonly seen in the
sixth to eighth decades, as in this series. EMP arising in the head
and neck characteristically presents with localized disease, and all
but two of the patients reported here had no clinical lymph node
involvement. These observations are in agreement with most of
the large reported series (Wiltshaw, 1976; Pahor, 1977; Kapadia et
al, 1982; Mayr et al, 1990; Shih et al, 1995).
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Figure 6 Bulky presentation of high-grade tumour outlined on magnetic
resonance imaging
Diagnostic criteria
The diagnostic criteria for EMP vary in different reported series.
Corwin and Lindberg (1979) and Mendenhall et al (1980) required
less than 10% plasma cells in the bone marrow, while Knowling et
al (1983) required normal bone marrow biopsy for the diagnosis of
EMP. Soesan et al (1992) has accepted the diagnosis of EMP for
those plasma cell tumours which presented in an extramedullary
site and did not arise from bone marrow with a breach through the
bone cortex. Most authors agree that the detection of a monoclonal
band on serum protein electrophoresis or urinary Bence Jones
protein does not necessarily preclude the diagnosis. It is estimated
that about 25% of EMP will show a monoclonal band of serum
protein at the time of diagnosis. The monoclonal gammopathy
disappears following treatment of localized primary tumour.
Subsequent development of a paraprotein may signal a recurrence
(Kapadia et al, 1982; Mock et al, 1987). Holland et al (1992) felt
that patients with paraprotein at the time of diagnosis fared worst,
while Harwood et al (1981), Soesan et al (1992) and Shih et al
(1995) suggested no effect on prognosis provided they return to
normal after treatment. Only one patient, in our series, had an IgA
monoclonal band on serum protein eletrophoresis at diagnosis, and
he has remained disease-free.
Bone destruction
The gross appearance of the tumour can be quite variable and can
appear as fleshy, yellowish grey to dark red sessile, polypoid or
pedunculated lesions. There may be destruction of adjacent bone
in direct continuity with the tumour mass. Poole and Marchetta
(1968), Gromer and Duvall (1973), Harwood et al (1981) and
Mock et al (1987) felt that the presence of bone destruction
seemed to be an unfavourable prognostic factor, while Kotner and
Wang (1972), Corwin and Lindberg (1979), Kapadia et al (1982)
and Mayr et al (1990) were not of the same opinion. In our series,
two ofthree tumours with bone destruction recurred locally; one of
them was a solitary high-grade EMP, and the patient presented
with a huge tumour in the paranasal sinuses (Figure 6). The higher
grade tumours were generally associated with more bulky disease.
The second patient had a primary tumour in the middle ear with
destruction of the petrous bone and was treated before the era of
computerized tomography scan localization. Therefore, we are
unable to comment on the effects of bone destruction as an inde-
pendent factor with respect to local control or conversion to
multiple myeloma.
Pathology
Histologically, plasmacytomas have the typical microscopic
appearance of a monomorphic infiltrate set in a sparse, delicate
and reticular stroma. The plasma cells themselves are character-
ized by round eccentric nuclei, with dense chromatin clumps
which are typically arranged along the nuclear membrane in a
'cartwheel' fashion. The cytoplasm is abundant and slightly
basophilic, usually with a paranuclear hof that corresponds to the
Golgi apparatus. Various forms of plasma cell atypia can be
encountered, depending on the degree of differentiation. While
atypia helps to establish the diagnosis of the plasma cell neoplasia,
definitive diagnosis of the latter requires demonstration of the
monoclonal character of the cell population, i.e. cells producing
either kappa or lamda light chain.
Kapadia et al (1982) graded their patients according to the
degree of atypia, mitoses and nuclear pleomorphism into well,
moderately and poorly differentiated tumours. They found that
four of six patients with poorly differentiated tumour died of
disseminated disease. Bartl et al (1987) has graded MM into a
three-tiered grading system to determine factors of value in
predicting prognosis. We extended their same grading system, for
the first time in the literature, to our cases of EMP. Our results
show a correlation between histological grading and local aggres-
siveness of disease. Of the 18 low-grade tumours, 15 (83%) were
controlled with primary XRT, and one recurrence after 60 months
was salvaged with further XRT. In the intermediate- and high-
grade group, only one of six patients treated radically was
controlled with primary XRT, although four of the recurrences
were salvaged with further treatment. The local control between
these low- and higher grade tumours are highly statistically signif-
icant (P = 0.0019), however overall survival is not (P = 0.12). This
leaves us with the question of whether the higher grade tumours
should be treated differently in terms of either XRT dose and
volume or the use of adjuvant chemotherapy.
Mock et al (1987), in a retrospective analysis of 18 cases of
EMP of the head and neck, found that the commonest immuno-
globulin was IgG with kappa light chain restriction. They observed
the lowest rate of progression to MM with IgG, and none of the
cases with kappa light chain restriction progressed to MM. They
suggested that those cases with lamda light chain may be more
immature and more likely to progress to MM. In our series, 65%
(16 of 25) had kappa and 28% (seven patients) had lambda light
chain restriction. Both ofthe cases that progressed to MM showed
kappa light chain restriction.
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Wiltshaw (1976) and Kapadia et al (1982) had noticed the pres-
ence ofabundant stromal amyloiddeposit inthebiopsy specimen in
their four patients and one patient, respectively, and could not find
any clinical correlation. Harwood et al (1981) had one patient with
abundant amyloid deposit in the biopsy specimen and observed a
slow rate ofregression afterXRT. Thepresence ofabundant stromal
amyloid deposit was seen in two patients in our series. One ofthese
patients locally recurred after 60 months and was reirradiated. He
later developed MM at 120 months and died from this at 144
months with local control of primary disease. The second patient
died of an unrelated cause at 24 months, with no evidence of
myeloma. Therefore, we could notfind any clinical correlation with
abundant stromal amyloid deposit in the biopsy specimen.
Radiotherapy
Mendenhall et al (1980), in a review ofthe literature, found a 94%
local control rate for localized plasmacytomas with doses in excess
of40 Gy in 4 weeks compared with only 69% when doses less than
40Gy were administered. KotnerandWang (1972) andWoodruffet
al (1979) recommended a dose of 40-50 Gy in 4-5 weeks, while
Petrovich et al (1977) felt that a dose of 60-80 Gy in 6-8 weeks
should be given. Todd (1965), from our institute, recommended a
dose of 30-33 Gy given over 3 weeks using kilovoltage X-rays.
Similarly, Harwood et al (1981) suggested 35 Gy in 3 weeks forthe
control of plasmacytomas. It is important to note that all the
reported series refer to a small number of patients and are spread
over a long period oftime with different XRT doses and fractiona-
tions. Our study suffers from the same problem and, therefore, we
are unable to determine a dose-response relationship. We can
conclude that our standard dose of35-45 Gy in 3 weeks with mega-
voltage photons did initially control 70% (10 of 14) of cases. Two
failures occurred in both the low- and higher grade tumour groups.
The presence of involved cervical lymph nodes at the time of
diagnosis is seen in 10-20% of cases (Kotner and Wang, 1972;
Kapadia et al, 1982; Mayr et al, 1990). We encountered two
patients (8%) with clinically involved cervical lymph nodes at
diagnosis. One ofthem is in remission and the second patient died
with uncontrolled disease after receiving palliative XRT. Several
studies suggest that the presence of involved cervical nodes at
diagnosis or subsequent development does not affect the survival
or conversion to MM (Poole and Marchetta, 1968; Kotner and
Wang, 1972; Corwin and Lindberg, 1979; Mocket al, 1987). Some
authors recommend prophylactic cervical lymph nodal XRT as it
was the first site ofrelapse in their patients (Knowling et al, 1983;
Greenberg et al, 1987; Mayr et al, 1990; Shih et al, 1995). It is our
policy not to treat cervical lymph nodes electively. Only one
patient with a clinically negative neck relapsed in cervical lymph
nodes after primary XRT.
Conversion to MM
Progression to MM varies from 10% to 30% in EMP and is signif-
icantly lower than progression to MM following solitary plasma-
cytoma ofbone (Wilthshaw, 1976; Knowling et al, 1983; Mayr et
al, 1990; Holland et al, 1992). The aggressive nature of solitary
plasmacytoma of bone in contrast to EMP is demonstrated by
Guida et al (1994). Our two patients (8%) who progressed to MM
did so after 6 and 120 months. Kapadia et al (1982) and Holland et
al (1992) found their patients progressed to MM within the first 2
years and suggested that this was the high-risk period. Most
authors recommend life-long follow-up as they have encountered
conversion to MM after 15 years (Rainer, 1970; Kotner and Wang,
1972; Gromer and Duvall, 1973; Wiltshaw, 1976; Pahor, 1977).
Management of local recurrences
Very few reported cases of local recurrence have been treated
primarily by surgery (Wiltshaw, 1976; Soesan et al, 1992). Surgery
is recommended if there is local failure after XRT in a resectable
tumour (Kotner and Wang, 1972). One of our cases had surgical
salvage. Two patients were retreated with XRT having relapsed
after 60 and 70 months. This was possible because plasmacytomas
are radiosensitive tumours when treated with moderate doses of
radiation, and relapse after a long interval permits retreatment.
The use ofchemotherapy is described in the literature in cases of
recurrence or disseminated disease with varying response. Kapadia
et al (1982) advocates chemotherapy in the adjuvant setting in large
or poorly differentiated tumours. Wiltshaw (1978) and Soesan et al
(1992) found better results when they treated the patients with
locally invasive disease with adjuvant alkylating chemotherapy.
The patient with a high-grade tumour who had a local recurrence
was treated with high-dose chemotherapy and peripheral blood
stem cell rescue. This approach, in use for MM (Fermand et al,
1995), has not been previously reported for recurrent EMP. This
has proved to be successful in contrast to the three patients treated
with alkylating chemotherapy ofmelphalan and prednisolone.
CONCLUSION
Extramedullary plasmacytoma (EMP) is a rare tumour which
predominantly occurs in the submucosa ofthe upper aerodigestive
tract. There is a strong male preponderance most commonly in the
sixth to eighth decades. From our clinicopathological correlation,
we conclude that tumour grading is the most important prognostic
factor. The grading criteria recommended for multiple myeloma
(MM) is applicable for EMP. We were unable to determine the
prognostic importance of adjacent bony involvement or clinically
involved lymph nodes. The majority of patients are elderly and
present with low-grade tumours. These low-grade tumours should
be treated with radiotherapy to the primary site with a dose equiv-
alent to 35-45 Gy in 3 weeks. The dose will depend on volume of
treatment and inclusion of critical structures but is well tolerated.
There is a place for retreatment with XRT if local recurrence
occurs after along interval. We do not advocate elective neck irra-
diation. Conversion to MM is significantly lower with EMP
compared with solitary plasmacytoma ofbone.
Tumours with higher grade EMP present with more bulky
disease and require large volume radiotherapy for control. The
poor local control with standard radiotherapy dose suggests that
higher doses should be used if these larger treatment volumes
permit; if not, we recommend treatment with adjuvant alkylating
chemotherapy in addition to local XRT for higher grade tumours -
this will reduce tumour bulk, enabling optimum local XRT to be
delivered. The use of intensive chemotherapy has a role in higher
grade tumour recurrence in patients with good performance status.
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